Charles River Laboratories International (CRL) Revenue — Quarter Ended Dec 30, 2023
Revenue for the quarter declined compared to both the prior quarter and the same quarter last year. The sequential decrease was modest, while the year-over-year drop was more pronounced.
Key takeaway
Quarter ended Dec 30, 2023 · FY2023 Q4
Revenue for the quarter declined compared to both the prior quarter and the same quarter last year. The sequential decrease was modest, while the year-over-year drop was more pronounced.
Financial snapshot
Reported revenue, sequential change, year-over-year change, and trailing four-quarter revenue.
Quarter revenue
$1B
Revenue reported for this quarter.
Quarter-over-quarter
-1.3%
Change from the immediately preceding quarter.
Year-over-year
-7.9%
Change from the comparable year-ago quarter.
Trailing four quarters
$4.1B
Sum of the latest four reported quarters.
Quarterly revenue trend
The latest four reported quarters with year-over-year comparisons.
| Period ended | Revenue | Year-over-year change |
|---|---|---|
| Apr 1, 2023 | $1B | +12.6% |
| Jul 1, 2023 | $1.1B | +8.9% |
| Sep 30, 2023 | $1B | +3.8% |
| Dec 30, 2023 | $1B | -7.9% |
Revenue performance
Reported revenue moved lower for the quarter, continuing a trend of deceleration from earlier periods in the fiscal year.
Quarterly comparison
Compared with the immediately preceding quarter, revenue contracted slightly. Versus the same quarter one year earlier, the decline was larger, reflecting a sharper year-over-year contraction.
What to watch
The filing discusses forward-looking statements and risks related to non-human primate supply chain investigations, which may affect future performance.